Enanta Pharmaceuticals, Inc. Reports Financial Results For Its Fiscal Fourth Quarter And Year Ended September 30, 2016
11/22/2016 10:25:22 AM
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal fourth quarter and year ended September 30, 2016.
Enanta’s cash, cash equivalents and short-term and long-term marketable securities totaled $242.2 million at September 30, 2016. Enanta expects that its current cash, cash equivalents and marketable securities will be sufficient to meet the anticipated cash requirements of its existing business for the foreseeable future.
comments powered by